Cytokine Signalling Forum

CME Courses




« Return to Overview

Focus on Tofacitinib

Developed by CESAS Medical, under the auspices of the University of Glasgow
This activity is supported by unrestricted educational grants from Pfizer Italia S.R.L., Lilly and R-Pharm.

Release date: 14 July 2017
Estimated time to complete activity: 1 hour 15 minutes
Compatible with all modern browsers and mobile devices

TARGET AUDIENCE
This activity is designed for rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with rheumatic disease.

PROGRAM OVERVIEW
Following the approval of tofacitinib in the European Union as well as by the FDA, this course provides an in-depth examination of emerging data with respect to the mechanism of action of tofacitinib, and efficacy data from the ORAL clinical trial programme in rheumatoid arthritis. An update regarding the safety of tofacitinib is provided, with clinical trials and real-life data presented. Current perceptions of tofacitinib are also discussed.

EDUCATIONAL OBJECTIVES
By following this programme, the learner will be able to:
  • Understand the JAK/STAT pathway and its implications on rheumatic disease
  • Understand the mechanism of action of JAK inhibitors
  • Evaluate the efficacy of tofacitinib across a number of patient groups
  • Understand the safety profile of tofacitinib in clinical practice

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

Please note that this course is currently awaiting accreditation.


Module Presenter Video Questions
Introduction
Professor Iain B. McInnes image
Professor Iain B. McInnes

Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
University of Glasgow, UK

Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.

Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.

Prof. Iain B. McInnes (Bio)
01:39
JAK-Kinase Targeting in RA: Mechanism of Action
Professor Iain B. McInnes image
Professor Iain B. McInnes

Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
University of Glasgow, UK

Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.

Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.

Prof. Iain B. McInnes (Bio)
30:28 4
Tofacitinib: Efficacy in Focus
Professor Peter Nash image
Professor Peter Nash

Associate Professor, Department of Medicine,
University of Queensland, Sunshine Coast, Australia

Peter Nash is Associate Professor at the Department of Medicine, University of Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia. He is Chair of the Professional Affairs committee and serves on the Scientific Advisory committee of the Australian Rheumatology Association, and also serves on the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. In addition, he is a member of the International Steering Committees of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Professor Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies. He has published over 100 peer-reviewed papers and four book chapters, and acts as reviewer for a number of journals. His special interests include metabolic bone disease and novel therapeutics.
Prof. Peter Nash (Bio)
17:46 5
Tofacitinib: Update on Safety
Professor Kevin Winthrop image
Professor Kevin Winthrop

Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology,
Oregon Health and Science University, USA

Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases.

Prof. Kevin Winthrop (Bio)
14:41 4
Evaluation 5

Date of preparation: 14 July 2017